© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 3, 198-205,
February 1995
© 1995 Oxford University Press
Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer
Affiliations of authors: LDS Hospital, Salt Lake City Utah
Radiation Therapy Oncology Group Headquarters Philadelphia, Pa
Rush Presbyterian Medical Center Chicago, III.
Vanderbilt Clinic Nashville, Tenn
University of Washington Hospital Seattle
The University of Texas M. D. Anderson Cancer Center Houston
B. Emami, Mallinckrodt Institute of Radiology St. Louis, Mo
Fox Chase Cancer Center Philadelphia
Zablocki VA Hospital Milwaukee, Wis
University of Michigan Medical Center Ann Arbor
London Regional Cancer Center Ontario, Canada
Correspondence to: William T. Sause, M.D., Radiation Therapy Department, LDS Hospital, 8th Ave. and C St., Salt Lake City, UT 84143.
Background: Regionally advanced, surgically unresectable non-small-cell lung cancer represents a disease with an extremely poor prognosis. External-beam irradiation to the primary tumor and regional lymphatics is generally accepted as standard therapy. The use of more aggressive radiation regimens and the addition of cytotoxic chemotherapy to radiotherapy have yielded conflicting results. Recently, however, results from clinical trials using innovative irradiation delivery techniques or chemotherapy before irradiation have indicated that patients treated with protocols that incorporate these modifications may have higher survival rates than patients receiving standard radiation therapy. Purpose: On the basis of these results, the Radiation Therapy Oncology Group (RTOG)-Eastern Cooperative Oncology Group (ECOG) elected to conduct a phase III trial comparing the following regimens: 1) standard radiation therapy, 2) induction chemotherapy followed by standard radiation therapy, and 3) twice-daily radiation therapy. Methods: Patients with surgically unresectable stage II, IIIA, or IIIB non-small-cell lung cancer were potential candidates. Staging was nonsurgical. Patients were required to have a Karnofsky performance status of 70 or more and weight loss less than 5% for 3 months prior to entry into the trial, to be older than 18 years of age, and to have no metas-tatic disease. Of the 490 patients registered in the trial, 452 were eligible. The disease in 95% of the patients was stage IIIA or IIIB. More than two thirds of the patients had a Karnofsky performance status of more than 80. Patients were randomly assigned to receive either 60 Gy of radiation therapy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period (standard radiation therapy); induction chemotherapy consisting of cisplatin (100 mg/m2) on days 1 and 29 and 5 mg/m2 vinblastine per week for 5 consecutive weeks beginning on day 1 with cisplatin, followed by standard radiation therapy starting on day 50; or 69.6 Gy delivered at 1.2 Gy per fraction twice daily (hyperfrac-tionated radiation therapy). Results: Toxicity was acceptable, with four treatment-related deaths. Three patients subsequently died of chronic pulmonary complications. Compliance with protocol treatment was acceptable. One-year survival (%) and median survival (months) were as follows: standard radiation therapy—46%, 11.4 months; chemotherapy plus radiotherapy—60%, 13.8 months; and hyperfractionated radiation therapy—51%, 12.3 months. The chemotherapy plus radiotherapy arm was statistically superior to the other two treatment arms (logrank P =.03). Conclusions: In "good-risk" patients with surgically unresectable non-small-cell lung cancer, induction chemotherapy followed by irradiation was superior to hyperfractionated radiation therapy or standard radiation therapy alone, yielding a statistically significant short-term survival advantage. [J Natl Cancer Inst 87: 198–205, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship Mayo Clin. Proc., May 1, 2008; 83(5): 584 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Huber, M. Flentje, M. Schmidt, B. Pollinger, H. Gosse, J. Willner, and K. Ulm Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group J. Clin. Oncol., September 20, 2006; 24(27): 4397 - 4404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart Imaging of the Patient with Non-Small Cell Lung Cancer Radiology, December 1, 2005; 237(3): 803 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Divers, S. A. Spencer, D. Carey, E. M. Busby, M. D. Hyatt, and F. Robert Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6664 - 6673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and G. A. Silvestri One Hundred Years of Lung Cancer Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 523 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results-Medicare J. Clin. Oncol., December 15, 2004; 22(24): 4971 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Marks, J. Garst, M. A. Socinski, G. Sibley, A. W. Blackstock, J. E. H. S. Zhou, T. Shafman, A. Tisch, R. Clough, X. Yu, et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium J. Clin. Oncol., November 1, 2004; 22(21): 4329 - 4340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hasegawa, S. Takanashi, K. Okudera, M. Aoki, K. Basaki, H. Kondo, T. Takahata, N. Yasui-Furukori, T. Tateishi, Y. Abe, et al. Weekly Paclitaxel and Nedaplatin With Concurrent Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: a Phase I/II Study Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 647 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski, C. Zhang, J. E. Herndon II, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M. C. Perry, S. L. Seagren, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity Ann. Onc., July 1, 2004; 15(7): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging Ann. Onc., March 1, 2004; 15(3): 389 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Sculier, J.-J. Lafitte, T. Berghmans, P. Van Houtte, J. Lecomte, J. Thiriaux, A. Efremidis, G. Koumakis, V. Giner, M. Richez, et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer Ann. Onc., March 1, 2004; 15(3): 399 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Albain, J. J. Crowley, A. T. Turrisi III, D. R. Gandara, W. B. Farrar, J. I. Clark, K. R. Beasley, and R. B. Livingston Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 J. Clin. Oncol., August 15, 2002; 20(16): 3454 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hahn, E. J. Bernhard, W. Regine, M. Mohiuddin, D. G. Haller, J. P. Stevenson, D. Smith, B. Pramanik, J. Tepper, T. F. DeLaney, et al. A Phase I Trial of the Farnesyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Lung and Head and Neck Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1065 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pottgen, W. Eberhardt, S. Bildat, G. Stuben, G. Stamatis, L. Hillejan, S. Sohrab, H. Teschler, S. Seeber, H. Sack, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial Ann. Onc., March 1, 2002; 13(3): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Esnaola, S. N. Lazarides, S. J. Mentzer, and K. M. Kuntz Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2002; 20(1): 263 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Komaki, M. H. Chasen, W. D. Travis, J. B. Putnam, F. V. Fossella, R. W. Byhardt, and J. Y. Ro Oncodiagnosis Panel: 1999: Cancer of the Lung: Oncodiagnosis RadioGraphics, November 1, 2001; 21(6): 1573 - 1596. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Robnett, M. Machtay, J. P. Stevenson, K. M. Algazy, and S. M. Hahn Factors Affecting the Risk of Brain Metastases After Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Carcinoma J. Clin. Oncol., March 1, 2001; 19(5): 1344 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Maguire, L. B. Marks, G. S. Sibley, J. E. Herndon II, R. W. Clough, K. L. Light, M. L. Hernando, P. A. Antoine, and M. S. Anscher 73.6 Gy and Beyond: Hyperfractionated, Accelerated Radiotherapy for Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2001; 19(3): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-R. Chien, S.-W. Chen, C.-Y. Hsieh, J.-A. Liang, S.-N. Yang, C.-Y. Huang, and F.-J. Lin Intra-thoracic Failure Pattern and Survival Status Following 3D Conformal Radiotherapy for Non-small Cell Lung Cancer: a Preliminary Report Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 55 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski, L.B. Marks, J. Garst, G.S. Sibley, W. Blackstock, A. Turrisi, J. Herndon, S. Zhou, M. Anscher, J. Crawford, et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: A Preliminary Report of a Phase I Dose Escalation Trial from the Carolina Conformal Therapy Consortium Oncologist, February 1, 2001; 6(2008): 20 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hayman, M. K. Martel, R. K. Ten Haken, D. P. Normolle, R. F. Todd III, J. F. Littles, M. A. Sullivan, P. W. Possert, A. T. Turrisi, and A. S. Lichter Dose Escalation in Non-Small-Cell Lung Cancer Using Three-Dimensional Conformal Radiation Therapy: Update of a Phase I Trial J. Clin. Oncol., January 1, 2001; 19(1): 127 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Johnson Locally Advanced, Unresectable Non-Small Cell Lung Cancer : New Treatment Strategies Chest, April 1, 2000; 117 (2009): 123S - 126S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani Combined Modality Therapy for Unresectable Stage III Non-Small Cell Lung Cancer : New Chemotherapy Combinations Chest, April 1, 2000; 117 (2009): 127S - 132S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M.W. Pisters, R. J. Ginsberg, D. J. Giroux, J. B. Putnam Jr, M. G. Kris, D. H. Johnson, J. R. Roberts, J. Mault, J. J. Crowley, and P. A. Bunn Jr INDUCTION CHEMOTHERAPY BEFORE SURGERY FOR EARLY-STAGE LUNG CANCER: A NOVEL APPROACH J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 429 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Sause, P. Kolesar, S. Taylor IV, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. Curran Jr., R. Byhardt, A. R. Dar, et al. Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest, February 1, 2000; 117(2): 358 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gandara, E. Vokes, M. Green, P. Bonomi, R. Devore, R. Comis, D. Carbone, D. Karp, and C. Belani Activity of Docetaxel in Platinum-Treated Non-Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial J. Clin. Oncol., January 5, 2000; 18(1): 131 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Sause The Role of Radiotherapy in Non-Small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 504S - 508S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Strauss Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 509S - 516S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Koukourakis, S. Koukouraki, A. Giatromanolaki, S. C. Archimandritis, J. Skarlatos, K. Beroukas, J. G. Bizakis, G. Retalis, N. Karkavitsas, and E. S. Helidonis Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3512 - 3521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life J. Clin. Oncol., October 1, 1999; 17(10): 3188 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Furuse, M. Fukuoka, M. Kawahara, H. Nishikawa, Y. Takada, S. Kudoh, N. Katagami, and Y. Ariyoshi Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2692 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Comella, G. Frasci, N. Panza, L. Manzione, V. Lorusso, G. Di Rienzo, R. Cioffi, G. De Cataldis, L. Maiorino, D. Bilancia, et al. Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group J. Clin. Oncol., May 1, 1999; 17(5): 1526 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Clamon, J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 1999; 17(1): 4 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Rice, D. J. Adelstein, J. P. Ciezki, M. E. Becker, L. A. Rybicki, C. F. Farver, M. A. Larto, and E. H. Blackstone Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Ann. Thorac. Surg., December 1, 1998; 66(6): 1909 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer and D. S. Ettinger The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy Oncologist, April 1, 1998; 3(2): 67 - 85. [Abstract] [Full Text]
|
|
|
|
|
|
Pretreatment Evaluation of Non-Small-cell Lung Cancer Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 320 - 332. [Full Text]
|
|
|
|
|
|
F. C. Detterbeck Pancoast (Superior Sulcus) Tumors Ann. Thorac. Surg., June 1, 1997; 63(6): 1810 - 1818. [Abstract] [Full Text]
|
|
|
|
|
|
J. Olak and A. Ng Diagnosis and Treatment of Early-Stage Non-Small Cell Lung Cancer Oncologist, August 1, 1996; 1(4): 201 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Edelman, D. R. Gandara, M. Roach III, and J. R. Benfield Multimodality Therapy in Stage III Non-Small Cell Lung Cancer Ann. Thorac. Surg., May 1, 1996; 61(5): 1564 - 1572. [Abstract] [Full Text]
|
|